- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 654
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- cisplatin, cyclophosphamide, vincristine sulfate, etoposide, therapeutic conventional surgery, 3-dimensional conformal radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 3 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Prostate Cancer
- Interventions
- Gefitinib plus etoposide
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging
- Procedure · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more
- Conditions
- Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
- Interventions
- RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 10
- States / cities
- Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide
- Biological · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- Up to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma
- Interventions
- Etoposide, G-CSF, GM-CSF, Isophosphamide, Rituximab, Apheresis
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 5
- States / cities
- Goldsboro, North Carolina • Winston-Salem, North Carolina • Greenville, South Carolina + 2 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 21
- States / cities
- Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
- Interventions
- SGN-40, placebo, rituximab, etoposide, carboplatin, ifosfamide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more
- Conditions
- Adult Burkitt Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Procedure · Drug · Biological
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- etoposide, topotecan hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- topotecan/cisplatin, etoposide/cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 66
- States / cities
- Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab, Carboplatin, Etoposide, Protein Phosphatase 2A Inhibitor LB-100
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Obatoclax, Carboplatin/etoposide
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more
- Conditions
- Small Cell Lung Carcinoma Extensive Disease
- Interventions
- Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 16 more
- Conditions
- Cardiac Toxicity, Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 36
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 28 more
- Conditions
- Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
- Interventions
- palifosfamide-tris
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- Kennewick, Washington • Kirkland, Washington • Seattle, Washington
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Round Cell Sarcoma, Metastatic Undifferentiated Sarcoma, Not Otherwise Specified, Round Cell Sarcoma With EWSR1-non-ETS Fusion, Sarcoma With BCOR Genetic Alterations
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Fludeoxyglucose F-18, Ifosfamide, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Regorafenib, Surgical Procedure, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more